Skip to content

Myeloproliferative Neoplastic Diseases Observatory From Brest

Observatoire Brestois Des Néoplasies Myéloprolifératives

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02897297
Acronym
OBENE
Enrollment
1000
Registered
2016-09-13
Start date
2015-09-01
Completion date
2025-09-30
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis

Brief summary

All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study. Myeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia and Primary Myelofibrosis. This is a not interventional study. Alive patients need to sign a non-opposition consent form. Patients will be followed until last news (death, change of reference centre...).

Detailed description

In this retrospective and prospective study, clinical and biological data from diagnosis until last news will be recorded. Clinical data collected: patients and disease characteristics at the time of the diagnosis, disease and mutational status, cardio-vascular risk factors, history of thrombosis and cancer. Biological data collected: hemogram and bone marrow results if available. During the follow-up new data will be noted: treatment changes (reasons of change and type of drug), thrombotic events (localization, date and hemogram), phenotypic evolutions (type and date), death (date and etiology).

Interventions

None listed

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis * Signature of the non-opposition consent form

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Overall Survival10 yearsoccurrence of death

Secondary

MeasureTime frameDescription
Incidence of evolutions10 yearsoccurrence of transformation into polycythemia vera, secondary myelofibrosis, myelodysplastic syndrome or acute leukemia
Incidence of thromboses10 yearsoccurrence of arterial or venous thrombotic events

Countries

France

Contacts

Primary ContactJean-Christophe Ianotto
jean-christophe.Ianotto@chu-brest.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026